Company release, 9 April 2021 at 12:10 p.m. (Finnish time)

Nightingale Health Plc’s fully owned subsidiary Nightingale Health Japan KK (together “Nightingale”), has been granted certificate of clinical laboratory for its Japan laboratory by the Prefectural Governor in Tokyo. Achieving status as clinical laboratory represents a very important milestone for Nightingale towards its commercial launch in Japan. Nightingale announced in the Prospectus published on 8th March 2021 that it is in the process of receiving laboratory certification in Japan, which is now successfully completed.

Teemu Suna, CEO and Co-founder of Nightingale:

“Achieving clinical laboratory certification constitutes another validation of the high quality standards we apply in all our global laboratories, and demonstrates our capability to adjust to the local requirements. We look forward to launching commercial operations in our Tokyo laboratory.”

Pasi Soininen, Laboratory Director and Co-founder of Nightingale:

“I am incredibly pleased that we have been granted clinical laboratory certification to our Japan laboratory. After securing this official confirmation of adherence to strict quality requirements and processes, we are ready to deliver results of our blood analysis to customers in Japan.”

About Nightingale

Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. By combining our pioneering blood-testing technology and the ability to detect future disease risks, we are creating a world-leading health data platform that enables preventative care with better information. The platform helps people make better personal health decisions and connects the health industry to offer their services for individuals’ preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone.

For further information, please contact:

Teemu Suna, CEO, tel. +358 20 730 1810

Certified Adviser:
Oaklins Merasco Ltd, tel. +358 9 6129 670